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INTRODUCTION
Cutaneous wound healing is a complex process that involves inflammation, keratinocyte/fibroblast proliferation, migration, angiogenesis, extracellular matrix (ECM) deposition and remodeling, all orchestrated by the specific actions of cytokines, chemokines, growth factors, and enzymes (Barrientos et al. 2008; Clark 2001; Martin 1997; Singer and Clark 1999) . One of these enzymes is Tumor necrosis factor (TNF)-stimulated gene-6 (TSG-6) protein, also known as TNF-induced protein 6 (Tnfip6 or Tnfaip6). TSG-6, first identified by Lee et al. (Lee et al. 1990 ) in human foreskin fibroblasts stimulated with the pro-inflammatory cytokine TNFa, encodes a secretory glycoprotein with a molecular weight of ~30-35 kDa (Milner and Day 2003; Mittal et al. 2016; Wisniewski et al. 1993) .
Functionally, TSG-6 appears to play important roles in ECM modification and in tissue inflammation. One of its important enzymatic activities is to catalyze the covalent transfer of heavychain (HC) protein from inter-alpha-trypsin inhibitor (IaI) and pre-a-inhibitor (PaI) to hyaluronan (HA) forming HC-HA complexes (Colon et al. 2009; Jessen and Ødum 2003; Mukhopadhyay et al. 2004 ). Due to this activity, TSG-6 has an important role in the stabilization and expansion of cumulus cell-oocyte complexes (COCs), a phenomenon vital for egg cell maturation, and thus accounting for female sterility in the TSG-6 null mouse (Fulop 2003; Fulop et al. 1997; Salustri et al. 1999; Salustri and Fülöp 1998) . Additionally, TSG-6 protein is able to inhibit neutrophil migration via the TSG-6 Link domain (Cao et al. 2004; Getting et al. 2002) which interacts with neutrophil chemokines such as human CXCL8, and with glycosaminoglycans (GAGs) on endothelial cell surfaces (Dyer et al. 2016; Dyer et al. 2014 ). Furthermore, TSG-6, as well as HC-HA complexes, have been shown to promote the polarization of macrophages to an alternatively activated/ anti-inflammatory M2 phenotype instead of the classically activated/ proinflammatory M1 phenotype (Ferrer et al. 2017; He et al. 2013; Mittal et al. 2016) . Given the ability of TSG-6 to regulate the behavior of neutrophils and macrophages, we postulated that TSG-6 may be important in cutaneous wound healing. However, evidence for this prior to our study was largely indirect.
Multiple investigations in other inflammatory disease models, such as rheumatoid arthritis and inflammatory colitis, suggested that TSG-6 expression is induced by inflammation and that its activity exerts anti-inflammatory effects (described more fully in the Discussion). In the skin, few previous studies on TSG-6 exist. Of those, one demonstrated the presence of TSG-6 and heavy chains HC1 and HC2 in human scars and keloids (Tan et al. 2011) . Another showed that intradermal implantation of mesenchymal stem cells (MSCs) in murine skin led to TSG-6 release, faster wound healing, less fibrosis, less macrophage activation, lower TNFa levels, and reduced granulation tissue formation relative to wildtype control wounds (Qi et al. 2014) . A third study investigated the effect of recombinant TSG-6 (rTSG-6) on rabbit ear wounds and showed that wounds injected with rTSG-6 healed with less hypertrophic scar than wounds receiving sham injections . Thus, available studies suggested that TSG-6 may play an antiinflammatory role in cutaneous wound healing. The aim of the current study was to test this hypothesis by examining how the loss of endogenous TSG-6 affects the normal course of wound repair in a knockout mouse model . Results of such experiments, we reasoned, could provide more insight into the potential for TSG-6 as a future therapy to enhance wound healing.
RESULTS

TSG-6 protein is present in unwounded murine skin, and its expression increases post wounding
To determine the endogenous expression of TSG-6 in normal and injured skin, Western analysis was performed on proteins from intact skin and full-thickness excisional wounds of wildtype (WT) mice (Figure 1a and b). TSG-6 is constitutively expressed at low levels in unwounded skin and increases by more than 4-fold as early as 12 h post-wounding. Expression peaks by 3 days, after which it drops but remains above baseline until at least day 10 ( Figure 1b ).
This shows that TSG-6 is upregulated after wounding, and suggests a possible functional role in wound repair.
As mentioned above, TSG-6 catalyzes the covalent transfer of HCs from IaI and pre-aI to HA, forming HC-HA complexes. HC-HA is thought to stabilize HA rich extracellular matrices, making it more adhesive to inflammatory cells (Lauer et al. 2014; Rugg et al. 2005; Zhuo et al. 2006; Zhuo et al. 2001) . To quantify the levels of HC-HA in unwounded and wounded WT skin, the assay shown in Figure 1c Figure 1d ). These changes mirror changes in expression of TSG-6 protein before and after wounding (Figure 1a and b).
There are no redundant enzymes that transfer HC to HA in the skin
To determine whether TSG-6 protein is the sole molecule responsible for HC-HA complex formation in skin, we assayed HC-HA in extracts from the skin of TSG-6 null mice biopsied preand post-wounding. The HC band normally seen in unwounded WT samples (Figure 1e Figure 1e , lane 6). These data verify that the loss of TSG-6 is responsible for the inability to form HC-HA complexes, and no other molecule is induced that can compensate and transfer HC from IaI to HA. Thus, this model was appropriate for our study to understand the effect of loss of TSG-6 and HC-HA complexes on cutaneous wound healing.
The absence of TSG-6 exerts major effects upon wound closure and neutrophil infiltration
Wound closure rate is an important indicator of proper wound healing. To observe the effects of loss of TSG-6 upon cutaneous wound closure, excisional wound areas were monitored over time in WT and TSG-6 null mice (Figure 2a and b). At all the time points post-wounding, the relative wound area was larger for TSG-6 null wounds compared to WT wounds, demonstrating that loss of TSG-6 delays wound closure. Differences were statistically significant at Days 5, 7 and 10 post-wounding.
Another critical measure of proper wound healing is the orchestrated recruitment and clearance of inflammatory cells. Neutrophils are among the first to arrive at the site of injury.
Interestingly, sections from early wounds (12 h and 24 h) immunostained with the neutrophilic granule marker Ly6G showed significantly fewer neutrophils in the TSG-6 null mice compared to WT mice (Figure 2c and d ). However, at later time points there were more neutrophils in TSG-6 null wounds, particularly at Day 7 where the difference was highly significant (Figure 2c and d) .
Thus, a differential pattern of neutrophil recruitment and/or clearance was observed in the presence versus absence of TSG-6 (and HC-HA) in cutaneous wounds.
To evaluate macrophages, we stained wound sections using the pan macrophage marker F4/80. No significant differences in the relative number of macrophages were observed between WT and TSG-6 null wounds, suggesting that the absence of TSG-6 and HC-HA had no significant effect upon total macrophage recruitment (Figure 2e and f).
TSG-6 null mice develop an abnormally pro-inflammatory wound milieu
TSG-6 is known to have anti-inflammatory effects in other systems (Day and Milner 2018) .
To assess the overall inflammatory status of wounds in TSG-6 null versus WT mice, we evaluated levels of TNF⍺ protein in whole wound tissue at different time points after injury, using Western analysis ( Figure 3a ). Consistently higher levels of TNF⍺ expression were found in TSG-6 null wounds than in WT wounds at all time points including unwounded skin at baseline ( Figure 3b ).
Thus, TSG-6 null wounds constitute a more pro-inflammatory environment than WT wounds.
Additionally, TSG-6 has been shown to play an important role in polarization of macrophages from a pro-inflammatory M1 to anti-inflammatory M2 phenotype. To determine whether macrophages in TSG-6 null wounds might be relatively more polarized toward an M1 phenotype compared to WT macrophages, we stained Day 7 wound sections for CD38 (an M1 marker), along with F4/80, in adjacent serial sections. Evaluation of these immunostains revealed that TSG-6 null wounds contain significantly more CD38-expressing macrophages than in WT wounds ( Figure 4a ). Next, we assessed the level of Arginase-1 (Arg1, an M2 marker) in whole wounds (Figure 4c ), both by immunostaining ( Fig. 4b ) and by western analysis (Figure 4e ). We found that Arg1 is consistently lower in TSG-6 null wounds at all time points evaluated, again suggesting a more pro-inflammatory environment in TSG-6 null wounds. To focus more closely upon the expression of M1/M2 phenotypic markers in the macrophages themselves, single cells were isolated from Day 5 wounds by dispase/collagenase digestion, followed by flow cytometric analysis of macrophages. We found that in TSG-6 null mice, a higher proportion of F4/80 positive macrophages expressed TNFa (a well-established M1 marker), while the proportion of macrophages expressing Arg1 was lower, relative to WT wounds (Figure 4d and e). Thus, the absence of TSG-6 in null wounds results in polarization of the overall macrophage population to a more proinflammatory phenotype.
Reintroduction of recombinant TSG-6 into TSG-6 knockout wounds restores normal healing
To confirm that the difference in wound closure observed in WT versus TSG-6 null wounds was due to the loss of TSG-6, a protein rescue experiment was performed. Recombinant TSG-6 protein (rTSG-6) was reintroduced at two time points, i.e., immediately after wounding (Day 0) and at 4 days post-wounding ( Figure 5a ). In TSG-6 null mice, wound sizes trended slightly lower at Days 1-5 in wounds receiving the rTSG-6 injections, and became significantly smaller (and equal to control WT wounds) at Day 7 (Figure 5b and c). Interestingly, injection of rTSG-6 into WT wounds worsened wound closure compared to the WT vehicle control. These findings suggested that the delay in wound closure in TSG-6 null wounds is attributable to loss of TSG-6.
To confirm that differences in neutrophil recruitment between WT and TSG-6 null wounds were also due to loss of TSG-6, a similar TSG-6 reintroduction experiment was performed. The experimental scheme was essentially the same as Figure 5a , but now wounds were harvested (either at 12 h or Day 7). Sections were immunostained for Ly6G. The number of neutrophils at the wound site at 12 h post wounding, which was reduced in TSG-6 null mice relative to WT, was significantly increased after one injection of rTSG-6 becoming similar to WT (however, WT wounds receiving rTSG-6 showed some delay in neutrophil recruitment) ( Figure 5d ). Likewise, the number of neutrophils observed in Day 7 wounds, ordinarily much higher in TSG-6 null wounds, was completely normalized to WT levels in mice receiving two rTSG-6 injections (Figure 5e ). Thus, the differential neutrophil recruitment observed in TSG-6 null wounds is reversible when TSG-6 is restored in the skin.
DISCUSSION
This study describes abnormal wound healing responses in mice lacking TSG-6, the enzyme that catalyzes cross-linking of heavy chain proteins to hyaluronan. Our overall findings show that relative to WT controls, TSG-6 null wounds display (i) delayed wound closure, (ii) delayed neutrophil recruitment in early wounds, (iii) exacerbated neutrophil recruitment in late wounds, and (iv) polarization of wound macrophages toward a pro-inflammatory ("M1") phenotype.
Reintroduction of recombinant TSG-6 can reverse both the delayed wound closure and the abnormal neutrophil recruitment.
Our study was motivated by previous literature suggesting an important role for TSG-6 in regulation of inflammation. In many cell and tissue types, TSG-6 expression is low or absent under normal condtions, but stimulated by pro-inflammatory factors such as TNFa, interleukin-1 (IL-1), and lipopolysaccharide (LPS) (Milner and Day 2003) . Here we show that TSG-6 is constitutively expressed at low levels in unwounded mouse skin, in agreement with earlier findings in human skin (Tan et al. 2011 ). However, TSG-6 expression is greatly increased after wounding. Similarly, HC-HA complexes are detectable in low amounts in normal skin and become significantly elevated after wounding. HC-HA is completely absent in the skin of TSG-6 null mice. Therefore, levels of TSG-6 appear to correlate with levels of its enzymatic product, HC-HA. Regarding wound inflammation, results reported after injection of rTSG-6 or MSCs (which produce TSG-6 along with many other factors) in other inflammatory models such as murine experimental arthritis (Bardos et al. 2001) , myocardial infarction (Lee et al. 2009 ), DSS-induced colitis (Sala et al. 2015) , and rabbit ear wounds , indicated that TSG-6 might have an anti-inflammatory role, resulting in decreased disease activity and/or improved recovery. In accordance with these studies, we found that absence of endogenous TSG-6 is deleterious to wound healing whereas restoration of the protein through direct dermal injection of rTSG-6 into TSG-6 null mouse wounds restored normal wound healing, at least in terms of the parameters evaluated here.
Beyond identifying a new wound-delay phenotype, our study provides several insights about inflammation and TSG-6 in wounds. Total loss of TSG-6 results in exacerbated pro-inflammatory effects in healing wounds. As a brief review, wounding initiates the release of multiple proinflammatory factors that stimulate local recruitment of neutrophils and monocytes into the wound bed (Martin and Leibovich 2005; Singer and Clark 1999; Wang 2018) . Neutrophil recruitment starts as early as 4 h post-wounding and plateaus around 3 days (Kim et al. 2008) .
Studies in other models in which rTSG-6 protein was injected into inflamed tissue revealed a decreased inflammatory response, including reductions in pro-inflammatory cytokines and neutrophil infiltration (Beltran et al. 2015; Kim et al. 2014; Oh et al. 2010 ); absence of TSG-6 on the other hand led to increased neutrophil infiltration (Szanto et al. 2004) .
Interestingly, in our TSG-6 null wound model the neutrophil recruitment response appears to be biphasic. At early timepoints (12 and 24 h post-wounding), neutrophils are significantly lower in TSG-6 null wounds than in WT wounds. To explain this, we postulate an interaction between neutrophils and HC-HA on the endothelial glycocalyx. It is known that the luminal side (endothelium) of blood vessels is lined with an HA rich glycocalyx (Reitsma et al. 2007; Shakya et al. 2015) , which we hypothesize under wound conditions becomes decorated with HC, forming HC-HA complexes. Because leukocytes bind more avidly to HC-HA complexes than to non-complexed HA (Lauer et al. 2014; Zhuo et al. 2006 ), HC-HA should facilitate neutrophil attachment within small vessels in the wound bed in WT wounds. Thus, the absence of HC-HA in TSG-6 null wounds should delay neutrophil recruitment in early wounds. However, in later wounds, mechanisms of neutrophil recruitment appear to be different since there is a relatively higher number of neutrophils in TSG-6 null wounds as compared to WT. The excessive levels of pro-inflammatory TNFa in TSG-6 null wounds may be one contributor to neutrophil overabundance especially at Day 7 where levels of TNFa and neutrophils are significantly higher in TSG-6 null wounds. TNFa elevation in TSG-6 deficient mice might occur via several mechanisms, e.g. through feedback inhibition pathways that become de-repressed upon loss of TSG-6, or via the action of cytokines released by incoming macrophages that stimulate cells in the wound bed to synthesize TNFa. Regardless of the recruitment mechanism, excessive neutrophil activity has been tied to delayed wound healing (Kim et al. 2008; Wilgus et al. 2013) , and is therefore a likely contributor to the aberrant wound healing observed in TSG-6 null mice.
Macrophages, the other major inflammatory cell type in wounds, remove apoptotic neutrophil debris and also secrete pro-inflammatory and anti-inflammatory cytokines, depending upon the particular macrophage phenotype (Koh and DiPietro 2011; Larouche et al. 2018; Wilgus et al. 2013 ). Although we found no significant difference in the absolute number of macrophages in TSG-6 null versus WT wounds, we did determine that macrophages in TSG-6 null wounds were skewed towards an M1 phenotype. This is in agreement with previous studies showing that and immobilized HC-HA complexes can drive macrophages to a more anti-inflammatory phenotype (Ferrer et al. 2017; He et al. 2013; Mittal et al. 2016) , and that TSG-6-producing MSCs can lower proinflammatory marker expression and increase anti-inflammatory M2 macrophages in a colitis model (Song et al. 2017) . From several lines of evidence, including the fact that M2 macrophages are known to promote tissue repair, and that M1 macrophages are greatly increased in chronic wounds such as diabetic ulcers, it is becoming clear that controlled regulation of macrophage phenotype is critical for proper wound healing (Hesketh et al. 2017; Khanna et al. 2010; Krzyszczyk et al. 2018) . Thus, we conclude that TSG-6 plays a crucial role in regulating macrophage phenotypes during cutaneous wound healing and this dysregulation in M1/M2 ratio in null wounds could be contributing to aberrant healing.
An additional factor to mention, because it could potentially contribute to the observed phenotypes, is an ability of TSG-6 to regulate chemokine function. As shown by Dyer et al., can regulate chemokine availability by competitive binding to various chemokines and/or sulfated GAGs in the ECM (Dyer et al. 2016; Dyer et al. 2014) . Absence of TSG-6 might interrupt some of these interactions and depending upon which cytokines are affected, could influence neutrophil migration. This possible mechanism would make an interesting subject for future investigation.
A strength of the current study is that TSG-6 restoration (rTSG-6 injection into TSG-6 deficient wounds) was shown to normalize wound closure and neutrophil recruitment. These results unambiguously establish that the defects observed in TSG-6 null mice result from loss of TSG-6 protein. Interestingly, while reintroduction of rTSG-6 into TSG-6 null wounds reversed the wound delay and neutrophil recruitment defects, addition of rTSG-6 into normal WT wounds worsened both of these phenomena. Apparently, tight regulation of TSG-6 is critical for proper wound healing, and either excessive or insufficient amounts are deleterious.
In summary, loss of TSG-6 leads to abnormal pro-inflammatory changes and is detrimental to wound healing, whereas a regulated amount of TSG-6 is crucial for a normal inflammatory response and proper wound closure. While more studies are needed to fully elucidate the mechanisms behind the phenotypes observed, our study provides important groundwork for understanding the role of endogenous TSG-6 in cutaneous wound healing.
MATERIALS AND METHODS
Animals
C57BL/6J mice were obtained from JAX Laboratories (Bar Harbor, ME). TSG-6 null mice, whose generation was described by Fülöp et al. (Fulop 2003) , was generously provided by Dr.
Mark Aronica in our institute. Mice were maintained per guidelines of the American Association for the Accreditation of Laboratory Animal Care. All procedures were approved by the Cleveland Clinic Institutional Animal Care and Use Committee (IACUC).
Wounding experiments
Mice (8-10 weeks old) were anesthetized via intraperitoneal Ketamine-Xylazine injection, and the upper back shaved with an electric razor. The next day, two full-thickness excisional wounds were made using 5 mm punch biopsies (Acuderm, Fort Lauderdale, FL) under anesthesia. To follow wound closure, mice were anesthetized with isofluorane and photographed from a fixed distance using a digital camera. Wound area was determined from the photos using standard imaging software. For histological examination, wound tissues were harvested at defined time points, fixed in Histochoice (Amresco, Solon, OH), and paraffin embedded. Other wound tissues were flash frozen in liquid nitrogen and stored at -80 °C for subsequent protein and RNA isolation.
Western Blotting
Protein lysates were prepared from wound samples as described previously (Mack and Maytin 2010) . Lysates were electrophoresed in NuPage 4-12 % Bis-Tris gels (Invitrogen, Carlsbad, CA), blotted onto PVDF membranes (Millipore, Burlington, MA), and probed overnight (4 °C) with one of the following primary antibodies: Anti-TSG-6 mouse monoclonal (1 µg/ml; Millipore); rat monoclonal TNFa (1 µg/ml; BioXCell, West Lebanon, NH); rabbit monoclonal Arg1 (1:1000, Cell Signaling Technology, Danvers, MA); rabbit anti-mouse Actin (1:1000; Santa Cruz Biotechnology, Dallas, TX). This was followed by 1.5 hour incubation with appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies (1:10,000; Jackson ImmunoResearch, West Grove, PA). Chemiluminescent detection was performed using Amersham™ ECL™, or ECL™ Prime reagent kits (GE Healthcare, Chicago, IL). Protein bands were quantified using IPLab Spectrum imaging software (Scanalytics, Rockville, MD).
Evaluation of HC modification of hyaluronan (HC-HA analysis)
HC-HA analyses were performed as described (Lauer et al. 2015) . Briefly, skin tissues were collected, weighed and minced in PBS at 1 µl volume per 0.33 mg of tissue. Streptomyces hyaluronidase (Millipore) was added (20 TRU/ml for extraction of HCs, or equal volumes of PBS for No-hyaluronidase controls), incubated for 30 min on wet ice followed by 30 min at 37 °C. After centrifugation (13,000 rpm), supernatants were collected, electrophoresed, and blotted.
Blots were incubated with anti-IaI rabbit polyclonal Dako antibody (1:8000; Agilent Technologies, Santa Clara, CA), followed by IRDye® 800CW donkey anti-rabbit secondary (1:15,000; LI-COR Biosciences, Licoln, NE). Blots were imaged on an Odyssey infrared imaging system (LI-COR Biosciences).
Immunostaining for neutrophils and macrophages
Paraffin embedded tissues were cut (5-micron sections), rehydrated, blocked with 3% normal goat serum for 30 min. Sections were incubated overnight (4 °C) with the respective primary antibodies: Anti-Ly6G rat monoclonal (1:100; Affymetrix, Santa Clara, CA) for neutrophils; Anti F4/80 rat monoclonal (1:100; Bio-Rad, Hercules, CA) for macrophages. A biotinylated goat anti-rat biotin secondary (1:300) was followed by Vectastain ABC reagent (Vector Laboratories, Burlingame, CA) for 30 minutes each. After detection using a DAB peroxidase substrate kit, mounted slides were scanned using an Aperio AT2 slide-scanner (Leica Biosystems, Buffalo Grove, IL). Areas positively stained for neutrophils or macrophages were evaluated using IPLab software (Scanalytics).
Immunostaining for macrophages phenotypes
Serial wound sections were incubated overnight (4 °C) with the respective primary antibodies: rabbit anti-mouse CD38 (1:100; Bioss, Woburn, MA) for M1 macrophages; rat monoclonal F4/80 (1:100; Bio-Rad) for all macrophages; rabbit monoclonal Arg1 (1:100; Cell Signaling Technology) for M2 macrophages. Sections were then incubated with goat anti-rat or goat antirabbit biotinylated secondary antibody (1:300; 30 min; Vector Laboratories) followed by incubation with Alexa Fluor 488 Streptavidin (1:500; 1.5 hour, Invitrogen), and mounted in VECTASHEILD mounting medium (Vector).
Flow cytometry for M1 and M2 macrophages
Single cell suspensions from Day 5 wounds were prepared as described (Bannon et al. 2013) with modifications. Briefly, wounds were isolated from WT and TSG-6 null animals and weighed. Tissues were rinsed once each in 70 % ethanol and PBS, cut into 2 mm 2 pieces and incubated overnight (4 ºC) in 20 µl HBSS per mg of wound tissue with 1 mg/mL Dispase II (Sigma-Aldrich, St. Louis, MO), 3% FBS and 10 mg/mL G418 (Sigma-Aldrich). Tissues were transferred to 80 µl HBSS per mg wound tissue with 1 mg/mL Collagenase I (Worthington, Lakewood, NJ), 75 U/mL DNaseI (Worthington) and 5 mg/mL G418, and incubated for 2 hours (37 ºC) with shaking. Cell suspensions were filtered through a 40 µm cell strainer (Corning Technology, Corning, NY) and washed twice with PBS buffer (PBS, 3% FBS, 0.1 mM EDTA), and centrifuged at 400 rpm. Cells were counted, resuspended at 1 million cells/ml in PBS buffer, and labeled with fluorescently tagged antibodies: Rat anti-mouse CD45 (1:200); rat antimouse F4/80 (1:80); rat anti-mouse TNFa (1:40; BioLegend, San Diego, CA); sheep anti-mouse Arg1 (1:10; Novus Biologicals, Centennial, CO) for 25 minutes (4 ºC). Samples were analyzed on a BD LSRFortessa flow analyzer (BD Biosciences, Mississauga, ON, Canada).
Recombinant TSG-6 injection
Mice were shaved, anesthetized, and two full thickness excisional wounds made using 5 mm punch biopsies. The edges and center of each wound was injected using an insulin syringe, with 2 µg of recombinant human TSG-6 (rTSG-6, R&D Systems, Minneapolis, MN) in 100 µl PBS (or with PBS alone) immediately after wounding and at Day 4 post wounding. Wounds were photographed to evaluate closure. Some wounds were collected at 12 h or Day 7 post wounding to evaluate neutrophil and macrophage infiltration.
Statistical analysis
All statistical analyses were performed using a two-tailed Student's t-test. A p-value < 0.05 was considered statistically significant. wound areas in WT and TSG-6 null mice +/-rTSG-6. Wound sizes are represented as percentage
